Catherine Coombs, MD, Discusses the Safety of Prolonged Pirtobrutinib in B-Cell Malignancies

Catherine Coombs, MD, of the University of California, Irvine, discusses her research on the long-term safety of pirtobrutinib in patients with relapsed or refractory B-cell malignancies who receive the therapy for at least 12 months. Dr. Coombs presented the study and its findings during the 2023 American Society of Clinical Oncology Annual Meeting.